CanSino Q1-Q3 2026 Net Profit Up 12.82% to 16.29 Million Yuan

The headline profit gain masks a sharper divergence underneath: nine-month revenue growth of 27.40% far outpaces net profit growth of 12.82%, and the third quarter shows the strain plainly, with revenue up only 7.17% while net profit fell 39.08%. The narrowing non-recurring net loss suggests the core operating picture is improving even as reported earnings soften quarter to quarter, which is the more telling signal for a vaccine maker still working toward durable profitability. Whether the Q3 margin compression is a one-off or the start of a cost trend is the open question worth tracking into the next reporting period.